Article

New Agent Shows Promise for MS

According to results of a multi-center, placebo-controlled phase IIb trial, patients treated with laquinimod, a new type of immumodulatory agent for relapsing-remitting MS, had a 40% reduction in lesions.

According to results of a multi-center, placebo-controlled phase IIb trial, patients treated with laquinimod, a new type of immumodulatory agent for relapsing-remitting MS, had a 40% reduction in lesions.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Related Content
Ankeet Bhatt, MD, MBA, ScM | Credit: American Heart Association
November 17th 2024

Understanding NUDGLE-FLU Data from AHA 2024, with Ankeet Bhatt, MD, MBA, ScM

Ankeet Bhatt, MD, MBA Patrick Campbell
Kidney Compass: Atacicept for IgAN with Jonathan Barratt, MD, PhD, at Kidney Week 2024
October 27th 2024

Kidney Compass: Atacicept for IgAN with Jonathan Barratt, MD, PhD, at Kidney Week 2024

Brendon Neuen, MBBS, PhD Shikha Wadhwani, MD, MS
Ellen Sher, MD | Credit: Allergy Partners
November 11th 2024

Ellen Sher, MD: Cross-Specialty Collaboration Can Improve Atopic Dermatitis Management

Ellen Sher, MD Patrick Campbell
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
April 17th 2024

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Jonathan Barratt, PhD | Credit: IgA Nephropathy Foundation
October 27th 2024

ORIGIN OLE Data Solidify Atacicept Disease-Modifying Potential for IgA Nephropathy

Patrick Campbell
Finnian McCausland, MBBCh | Credit: Mass General Brigham
October 25th 2024

Finerenone Use Reduces UACR, New-Onset Macroalbuminuria in Heart Failure Patients

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.